Latest News - BioTime

Monday, August 14, 2017 | Retina, AMD, BioTime

BioTime Announces $2 Million Grant for Further Development of OpRegen for Dry AMD

BioTime has been awarded a new grant for 2017 of up to 7.2 million Israeli New Shekels (approximately $2 million) from the Israel Innovation Authority (IIA) to fund the continued development of OpRege…

Read the full story

Wednesday, July 19, 2017 | Clinical Trials, AMD, BioTime

Data From BioTime’s Phase 1/2a OpRegen Trial to be Presented at the 2017 AAO Annual Meeting

BioTime announced that an abstract related to the company’s retinal tissue implant has been accepted for a paper presentation at the American Academy of Ophthalmology (AAO) annual meeting being …

Read the full story

Monday, June 19, 2017 | Clinical Trials, BioTime

Biotime Expands & Advances Ophthalmology Portfolio

BioTime reported several developments for its ophthalmology portfolio, including: Signing a new and expanded licensing agreement with Hadassah Medical Organization of Jerusalem, Israel Present…

Read the full story

Thursday, May 11, 2017 | Medical Studies, BioTime

BioTime Presents Retinal Restoration Data at ARVO

BioTime announced that a poster related to the company’s retinal restoration technology was presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in …

Read the full story

Wednesday, May 10, 2017 | Clinical Trials, BioTime

BioTime Announces New Positive Data from OpRegen Trial in Dry-AMD

BioTime announced new data from the phase 1/2a clinical trial of OpRegen in the advanced form of dry age-related macular degeneration (AMD). The interim data were presented on May 8, 2017 at the …

Read the full story